{"denomUnitsSelected":"Participants","description":"Kaplan-Meier methodology will be used to estimate the distribution of\\>\\>\\> OS.","reportingStatus":"NOT_POSTED","timeFrame":"Time between date the patient initiated sapanisertib and death due to any cause (or last contact for surviving patients and those lost to follow-up), assessed up to 2 years","title":"Overall Survival (OS) in Crossover Patients (Phase II)","type":"OTHER_PRE_SPECIFIED"}